- Asmar M, Simonsen L, Asmar A, et al. Insulin plays a permissive role for the vasoactive effect of GIP regulating adipose tissue metabolism in humans. J Clin Endocrinol Metab 2016;101(8):3155–62.
- Getty-Kaushik L, Song DH, Boylan MO, et al. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity (Silver Spring) 2006;14(7):1124–31.
- Newgard CB. Metabolomics and metabolic diseases: where do we stand? Cell Metab 2017;25(1):43–56.
- Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17(4):448–53.
- Flores-Guerrero JL, Osté MCJ, Kieneker LM, et al. Plasma branched-chain amino acids and risk of incident type 2 diabetes: results from the PREVEND prospective cohort study. J Clin Med 2018;7(12):513.
- Lotta LA, Scott RA, Sharp SJ, et al. Genetic predisposition to an impaired metabolism of the branched-chain amino acids and risk of type 2 diabetes: a mendelian randomisation analysis. PLoS Med 2016;13(11):e1002179.
Perspectives
How does this study impact clinical practice?
- It is already known that tirzepatide reduces body weight and improves glycemic control.
- These results show that tirzepatide also uniquely modulates metabolites associated with T2D risk and metabolic dysregulation consistent with improved metabolic health.
- These metabolomic findings help to gain insight into the mechanisms that contribute to the multiorgan metabolic dysregulation driving T2D pathogenesis.
- Additional mechanistic studies are ongoing to better understand the beneficial effects of GIP receptor agonism.
